Vaxxinity CEO Mei Mei Hu Speaking at White House Summit on the Future of COVID-19 Vaccines
26 July 2022 - 1:57AM
Vaxxinity, Inc. (Nasdaq: VAXX) Chief Executive Officer Mei Mei Hu
will participate as a speaker at the White House Summit on the
Future of COVID-19 Vaccines. Hu is honored by the invitation and
eager to engage in discussion on the critical importance of
developing innovative, next-generation COVID-19 vaccines that are
more well tolerated, easier to make, longer-lasting, and more
effective against future variants.
The one-day summit hosted by the Biden-Harris
Administration White House Office for COVID-19 Response brings
together U.S. scientists and companies on the cutting-edge of
discoveries in the vaccine space to discuss the paths to accelerate
innovative, next-generation COVID-19 vaccines along with design and
manufacturing advances that can be scaled to meet demand and offer
people more choices.
Hu is speaking on the first panel discussion
titled, “Next-Generation Vaccine Design and Manufacturing.”
“I’m humbled to speak alongside vaccine leaders
on this White House Summit panel discussing the next generation of
COVID-19 vaccines,” said Hu, Chief Executive Officer of Vaxxinity.
“COVID is here to stay and we must develop better tools to fight
it. America led the charge in 2020, and now it’s time for America
to lead again. Continued innovation beyond first-generation
vaccines is crucial if we are to build public confidence, provide
people choice and protect against potential future variants. Key to
this will be COVID boosters with fewer side effects, broader
coverage and longer protective duration that can be domestically
manufactured and globally distributed more efficiently. The
Vaxxinity team is developing a next generation COVID booster,
UB-612, with the potential to meet these needs.”
About VaxxinityVaxxinity, Inc.
is a purpose-driven biotechnology company committed to
democratizing healthcare across the globe. The company is
pioneering a new class of synthetic, peptide-based
immunotherapeutic vaccines aimed at disrupting the existing
treatment paradigm for chronic disease, increasingly dominated by
monoclonal antibodies, which suffer from prohibitive costs and
cumbersome administration. The company’s proprietary technology
platform has enabled the innovation of novel pipeline candidates
designed to bring the efficiency of vaccines to the treatment of
chronic diseases, including Alzheimer’s, Parkinson’s, migraine, and
hypercholesterolemia. The technology is also implemented as part of
a COVID-19 vaccine program. Vaxxinity has optimized its pipeline to
achieve a potentially historic, global impact on human health.
For more information about Vaxxinity, Inc.,
visit http://www.vaxxinity.com and follow us on social media
@vaxxinity.
Forward-looking StatementThis
press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
The use of certain words, including "potential," and "will" and
similar expressions, are intended to identify forward-looking
statements. These forward-looking statements involve substantial
risks and uncertainties, and are based on the current expectations
and assumptions of Vaxxinity’s management. Forward-looking
statements include statements about the development of a new class
of immunotherapeutic vaccines and the innovation and efficacy of
Vaxxinity’s product candidates. Various important factors could
cause actual results or events to differ materially from those that
may be expressed or implied by our forward-looking statements.
Additional important factors to be considered in connection with
forward-looking statements are described in the "Risk Factors"
section of the Company's Annual Report on Form 10-K filed with the
Securities and Exchange Commission on March 24, 2022 and other
reports we file with the Securities and Exchange Commission. The
forward-looking statements are made as of this date and Vaxxinity
does not undertake any obligation to update any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as required by law.
Investor ContactBen
Matonebenm@vaxxinity.com
Press ContactKaren Chasemedia@vaxxinity.com
Vaxxinity (NASDAQ:VAXX)
Historical Stock Chart
From Apr 2024 to May 2024
Vaxxinity (NASDAQ:VAXX)
Historical Stock Chart
From May 2023 to May 2024